Abstract 937P
Background
Pain, fatigue and depression are commonly seen in cancer survivors and may co-occur. The extent of these symptoms occurring, alone or together, in head and neck cancer (HNC) is unknown. Using data from the Head and Neck 5000 cohort, we (i) investigated prevalence of the pain, fatigue, depression symptom cluster and (ii) explored its association with health-related quality of life (HRQoL).
Methods
Sociodemographic and clinical data were collected from participants at cohort recruitment (pre-treatment). At 12-months post-recruitment, cancer-related pain, fatigue and HRQoL were measured using the EORTC QLQ-C30, and depression using the Hospital Anxiety & Depression Scale (HADS). Cut-offs to define presence of clinically-important symptoms were: pain ≥25, fatigue ≥39 and depression ≥8. Associations between HRQoL score (on scale 1-100; higher score=better HRQoL) and the symptom cluster (0/1/2/3 symptoms), adjusted for clinical and sociodemographic variables, were assessed using multivariate linear regression.
Results
2,207 patients were included in the analysis. 47.3% had one or more symptoms of pain, fatigue or depression at clinically important levels. 20.3% had any one symptom, 13.7% had any two symptoms and 13.4% had all three symptoms. In the multivariate analysis, number of symptoms was strongly associated with HRQoL. After adjusting for other variables, presence of any one symptom was associated with a 13.4 point decrease (95% CI -15.2 to -11.7) in HRQoL, any two symptoms with a 26.3 point decrease (95% CI -28.3 to -24.3) and all three symptoms with a 42.3 point decrease (95% CI -44.3 to -40.2) in the HRQoL.
Conclusions
There is a high prevalence of the pain, fatigue and depression cluster in HNC survivors with over one in ten experiencing all three symptoms at 12-months. They have a significant negative impact on HRQoL. More attention should be given to identifying survivors experiencing this symptom cluster. Interventions targeted at addressing the cluster symptoms may help improve HRQoL amongst HNC survivors.
Clinical trial identification
N/A
Editorial acknowledgement
Funding
National Institute for Health and Care Research (NIHR).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1036P - Large-scale cellular profiling of 1283 cancer patients reveals a NK cell-mediated immunosuppressive tumor microenvironment in immunotherapy resistance
Presenter: Yumo Xie
Session: Poster session 03
1037P - Activating strong anti-tumor immunity with PTPN2/PTPN1 inhibitor: AC484
Presenter: Hakimeh Ebrahimi-Nik
Session: Poster session 03
Resources:
Abstract
1038P - Interactions of immune checkpoint blockade and regulatory T cells
Presenter: Dylan Muldoon
Session: Poster session 03
1039P - Discovery of a novel inhibitor of PD-L1 maturation that overcomes adaptive resistance to cancer immunotherapy
Presenter: Eduard Teixidor Vilà
Session: Poster session 03
1040P - Chemotherapy remodels the tumor immune microenvironment to increase the pCR rate of anti-PD-1 neoadjuvant therapy in MSS/pMMR locally advanced colon cancer: A prospective clinical trial and translational study
Presenter: Changjing Cai
Session: Poster session 03
Resources:
Abstract
1041P - ODI-2001, a personalized combinatorial immunotherapy shows antitumoral activity across different syngeneic mice tumor models, including 4T1
Presenter: Pierre MARSCHALL
Session: Poster session 03
1042P - Rapid, single-step monitoring of circulating monoclonal antibodies using an aptamer-based electrochemical sensing platform
Presenter: Raffaella Ergasti
Session: Poster session 03
1043P - Advancing a multi-dimension KRAS mutation-specific T cell receptor (TCR) library with a 3S TCR targeting the G12D mutation to address large global patient populations
Presenter: Kirsty Crame
Session: Poster session 03
1044P - UniTope & TraCR: Universal tagging and tracking system for TCR-T cells integrated directly in the TCR constant region
Presenter: Kirsty Crame
Session: Poster session 03
1045P - The association of human leukocyte antigen variants in immune-related toxicity and efficacy in Chinese lung cancer patients treated with immune checkpoint inhibitors
Presenter: Yongchang Zhang
Session: Poster session 03